Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > REGULATORY
REGULATORY
- ICH Assembly to Make Final Decisions on All Important Issues: PMDA Official
July 27, 2015
- Japan Embarking on Biosimilar Development, but It’s a Race against Time: MHLW Official
July 24, 2015
- Japan Eyes Linking Dormant Pricing Premium with Sakigake System, Upping Rate to 20% at Maximum
July 24, 2015
- Chuikyo Subcommittee OKs Plan to Draft GL for Analyzing Cost-Effectiveness; QALY Expected to Be Main Index
July 24, 2015
- Drug Pricing Organization Proposes Re-Pricing of Products with Huge Sales
July 23, 2015
- Kaketsuken Withdraws Earlier Explanation of Blood Products Scandal; Problem Discovered through Information Provided to MHLW
July 23, 2015
- AMED Takes Initial Step Toward Out-Licensing First Lead Compound; Now Taking Applications from Companies
July 23, 2015
- PMDA Calls for Caution for Use of Inavir, Relenza in Patients Allergic to Milk Products
July 23, 2015
- MHLW Raises Flag on Vaccine Expiration Dates after Imovax Polio Mishaps
July 22, 2015
- MHLW Panel OKs Shipment of 2 Kaketsuken Blood Products
July 22, 2015
- Govt Sets FY2016 Budget Allocation Policy for Healthcare R&D
July 22, 2015
- Z2 Rule, DPC Incentive Need Revisions in Line with New Generic Target: MOF Budget Examiner
July 22, 2015
- Second Committee on Drugs to Discuss Approval of AZ’s Vandetanib at Meeting on Aug. 3
July 22, 2015
- Editor’s Pick: Five Healthcare News Headlines for July 6 - July 20
July 21, 2015
- PAFSC’s First Committee to Discuss Actelion’s Tracleer, Other Products on July 31
July 21, 2015
- Filings for Investigator-Led Trials Log 6-Fold Increase in 6 Years: PMDA Official
July 17, 2015
- Government’s Council Finalizes Policy Proposal for Promoting Genomic Medicines for Rare Diseases, Diabetes
July 16, 2015
- Drug Pricing Tomorrow: Full Interview with MHLW Economic Affairs Head Jo - Part 2
July 15, 2015
- MHLW Starts Seeking Drug Development Requests under New Scheme
July 14, 2015
- Council OKs Applications Based on Data from Public Domain for 3 Drugs Including Lidocaine
July 14, 2015
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…